Abstract | AIM: METHODS: Cells of primary colorectal carcinomas were from 8 patients. Immunostaining and crystal violet staining were used for analysis of growth factor receptor protein expression and detection of cell number changes, respectively. Cytotoxicity was determined by measuring the release of the cytoplasmic enzyme lactate dehydrogenase (LDH). The proportion of apoptotic cells was determined by quantifying the percentage of sub-G1 (hypodiploid) cells. Cell cycle status reflected by the DNA content of the nuclei was detected by flow cytometry. RESULTS: CONCLUSION:
|
Authors | Michael Hopfner, Andreas P Sutter, Alexander Huether, Viola Baradari, Hans Scherubl |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 12
Issue 35
Pg. 5635-43
(Sep 21 2006)
ISSN: 1007-9327 [Print] United States |
PMID | 17007015
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Cytotoxins
- Fatty Acids, Monounsaturated
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Indoles
- NVP-AEW541
- Pyrimidines
- Pyrroles
- Fluvastatin
- L-Lactate Dehydrogenase
- Receptor Protein-Tyrosine Kinases
- Receptor, IGF Type 1
- Cetuximab
|
Topics |
- Adenocarcinoma
(drug therapy, metabolism, pathology, prevention & control)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Apoptosis
(drug effects)
- Cell Cycle
(drug effects)
- Cell Line, Tumor
- Cetuximab
- Colorectal Neoplasms
(drug therapy, metabolism, pathology, prevention & control)
- Cytotoxins
(therapeutic use)
- Dose-Response Relationship, Drug
- Fatty Acids, Monounsaturated
(therapeutic use)
- Fluvastatin
- Gene Expression Regulation, Neoplastic
(drug effects)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Indoles
(therapeutic use)
- L-Lactate Dehydrogenase
(genetics, metabolism)
- Pyrimidines
(pharmacology, therapeutic use)
- Pyrroles
(pharmacology, therapeutic use)
- Receptor Protein-Tyrosine Kinases
(antagonists & inhibitors, drug effects, genetics, metabolism)
- Receptor, IGF Type 1
(antagonists & inhibitors, drug effects, genetics, metabolism)
|